Study opens new avenue for immunotherapy drug development
In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed a new method for developing immunotherapy drugs using engineered peptides to elicit a natural immune response inside the body.
In preclinical models of locally advanced and metastatic breast cancer, this method improved tumor control and prolonged survival, both as a monotherapy and in...
AACR: Trio of studies highlights promising early results with new cancer therapies and targets
ABSTRACTS CT037, CT038, CT042
Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson...
AACR: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients...